

*Håkan Hanberger, is senior consultant in infectious diseases in critical care, professor at the University of Linköping, chair of Swedish Reference Group of Antibiotic and WHO consultant. He is the leader of a research group studying antibiotic resistance (ABR) and hospital acquired infections (HAI) in low/middle and high income countries. His interests are in the fields of surviving, sepsis, critical care, interventions against ABR and HAI and mechanisms of ABR.*

## **CV Håkan Hanberger**

Borne 1954, married, 3 sons.

**1. Higher education qualifications:** 1980 MD 1980 at the University of Linköping, Sweden.

**2. Doctoral degree:** PhD 1992, Hälsouniversitetet i Linköping, Linköping University. Title: Pharmacodynamic effects of antibiotics, Studies on bacterial morphology, initial killing, post antibiotic effect and effective regrowth time

**3. Postdoctoral scholarship,** Swedish Society for Medical Research 1992-1994, Sweden.

**4. Appointment as a docent** 1999

**5. Specialist Infectious Diseases** 1987.

### **6. Present positions;**

- a. *Senior physician/professor;* adj. professor 2008-2013, full professor promotion 2014-, currently 33% time for research,
- b. Chairman Swedish Reference Group of Antibiotics, Swedish Institute for Communicable Disease Control/Swedish Society of Medicine 2012- .
- c. Chief Anti-infective Drugs, Drug committee County Council of Östergötland 1994- .
- d. Member of National Steering Committee of Strama (Swedish Strategic Programme against Antibiotic Resistance), 2005- .
- e. Member of Scientific Council of Swedish Medical Product Agency, 2014-
- f. WHO consultant in Antibiotic Resistance

### **7. Previous positions and periods of appointment;**

- a. PhD-scholarship (LiU central doktorandtjänst) Linköpings Universitet 1991-1992,
- b. Senior Teacher and Researcher Faculty of Health Sciences, Linköping University (universitetslektor (vik.), adjungerad lektor), 1998-2008 ,
- c. Senior physician (specialistläkare, biträdande överläkare, överläkare) Department of Infectious Diseases in Östergötland, County Council of Östergötland/Infectious Diseases 1988-2008 ,
- d. Investigator/research coordinator IPSE (Improved Patient Safety in Europe), European Commission Health and Consumer Protection Directorate General; DG-SANCO)/ Swedish Institute for Communicable Disease Control, 2005-2008 (part time),
- e. Consultant expert infection in intensive care European Centre for Disease Prevention and Control (ECDC), Solna Sweden, 2009, (part time),
- f. Chairman of ICU Strama (Intensive Care Section in Swedish Strategic Programme against Antibiotic Resistance), 2001- 2010 (part time),
- g. Senior physician/professor, Akershus Oslo Universitet, 2009 (not acceded)

**8. Interruption in research;** Parental leave, 11 months, 1987, 1989, 1993

### **9. Supervision**

*PhD candidates supervised up to the defense of the candidate's doctoral thesis, with the applicant serving as main supervisor*

- a. Baharak Saeedi 2005, LiU
- b. Marcus Erlandsson 2007, LiU
- c. Annika Samuelsson 2013, LiU

*PhD candidates supervised up to the defense of the candidate's doctoral thesis, with the applicant serving as co-supervisor*

- a. Erik Svensson 1997, LiU
- b. Anita Hällgren 2005, LiU
- c. Carina Claesson 2010, LiU
- d. Fredrik Hammarskjöld 2013, LiU
- e. Åse Östholm 2014, LiU,
- f. Vu Dinh Phu 2017, UK/Vietnam/Sweden

Ongoing supervision of a PhD candidate,

- a. Martin Holmbom, ongoing, main supervisor, LiU
- b. Maria Andersson, ongoing, main supervisor, LiU
- c. Vidar Möller, newstartade, main supervisor, LiU
- d. Jonas Andersson Lindholm, co-supervisor, KI
- e. Knut Taxbro, co-supervisor, LiU

## **10. Selected academic distinctions**

*Elected to the following positions:*

- a. ESGAP executive committee (ESCMID Study Group for Antibiotic Policies)
- b. ESGNI executive committee (ESCMID Study Group for Nosocomial Infections)
- c. Steering committee IPSE: Improving Patient Safety in Europe IPSE (WP leader, coordinator):
- d. Scientific Committee EPIC II (Global Study on Infection in Intensive Care)
- e. Clinical Advisory Board: Detecting and Eliminating Bacteria Using Information Technologies (DebugIT).
- f. Swedish Research council experts for JPIAMR (Joint Programming Initiative on Antimicrobial Resistance).
- g. Program committee: ECCMID 2013.
- h. European Network of Antimicrobial Clinical Trials, coordinator Swedish Hope (hospitals) — New Drugs for Bad Bugs NN4BB ABSSI/CABP, within Innovative Medicines Initiatives (IMI).
- i. European Guideline committee for Hospital Acquired pneumonia. ERS/ESCIM/ESCMID/ALAT
- j. Scientific Council of Swedish Medical Product Agency

*Teaching assignments*

- a. Lecturer and chairman at numerous national and international meetings within my research area and in general on intensive care infections.
- b. Organized several international interactive workshops within my competence, i.e. resistance to antibiotics and intensive care infections.
- c. Lecturer and organizer of national post graduate courses.
- d. Project manager for educational activities on antibiotic treatment guidelines, infections control and antibiotic resistance on behalf of Östergötland drug committee and Strama
- e. Course leader for a yearly 5 days course in sepsis management. Target groups are trainees in infectious diseases, intensive care and emergency medicine. The course is required for residency, case-based interactive methods including full-scale simulations in clinical laboratories. Third edition of "The Sepsis book" (proceedings of the course) published 2017. The sepsis book includes Swedish treatment guidelines.
- f. Head teacher in infectious diseases at the medical school, Linköping University. Long experience of teaching design in problem-based learning.